Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer - Trial NCT06221462
Access comprehensive clinical trial information for NCT06221462 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ningbo No.2 Hospital and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ningbo No.2 Hospital
Timeline & Enrollment
Phase 2
Feb 01, 2024
Feb 01, 2030
Primary Outcome
major pathological response (MPR)
Summary
This is a prospective single-center, open-label, phase II study evaluating the efficacy of
 sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable
 non-small cell lung cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06221462
Non-Device Trial